Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

v2.4.0.8
Commitments and Contingencies - Additional Information (Detail) (USD $)
0 Months Ended 3 Months Ended 0 Months Ended 1 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended
Oct. 16, 2012
Aug. 31, 2014
Aug. 31, 2014
Progenics Pharmaceuticals, Inc
Jan. 20, 2014
Project Work Order
Project
Dec. 31, 2013
Project Work Order
Aug. 31, 2014
Project Work Order
Aug. 31, 2014
Project Work Order
One Study
Aug. 31, 2014
Project Work Order
Amarex Clinical Research, LLC
Aug. 31, 2014
Milestone Payments
US Phase III trial
Aug. 31, 2014
Milestone Payments
US new drug application approval by the FDA
Aug. 31, 2014
Development Milestone Payments
Aug. 31, 2014
Development Milestone Payments
US Phase III trial
Aug. 31, 2014
Development Milestone Payments
US new drug application approval by the FDA
Aug. 31, 2014
Development Milestone Payments
New Drug Application with the FDA
Aug. 31, 2014
Director
Aug. 31, 2014
Director
Stock Option Award Agreement dated Dec 6,2010
Aug. 31, 2014
Director
Stock Option Award Agreement dated September 22,2010
Aug. 31, 2014
Director
Stock Option Award Agreement dated April 16,2012
Commitment And Contingencies [Line Items]                                    
Salary                             $ 13,890      
Cash severance payment                             13,890      
Severance period                             33 months      
Reimbursement of health insurance period                             9 months      
Stock option award agreement                               500,000   750,000
Stock Option granted, per share                               $ 1.19   $ 2.00
Options granted                                 25,000  
Option immediate vesting                                   1,500,000
Options forfeiture                                   750,000
Severance expense   42,000                                
Severance liabilities   153,000                                
Asset purchase, cash paid 3,500,000               1,500,000 5,000,000   1,000,000 500,000 500,000        
Royalty on every net sales     5.00%               7.50%              
Asset Purchase Agreement Aggregate Consideration Paying Period   10 years                 10 years              
Minimum annual license maintenance fees                     150,000              
Number of research studies projects       2                            
Number of projects terminated       1                            
Project termination notice period       30 days                            
Estimated combined cost of two separate studies           9,300,000                        
Estimated cost terminated without penalty             4,300,000                      
Estimated remaining cost           3,700,000   1,000,000                    
Payment to CRO for deposit         790,000                          
Termination period upon prior notice           30 days                        
Percentage of remaining contract amount for direct services to be paid upon termination           30.00%                        
Postponed research studies amounts allowed to be applied to all amounts due to the CRO           $ 343,000